Nexalin Technology (NXL) Long-Term Deferred Tax (2021 - 2022)
Nexalin Technology (NXL) posted quarterly Long-Term Deferred Tax of $3.3 million for Q4 2022, up 12.91% year-over-year from $3.0 million in Q4 2021, and up 12.91% quarter-over-quarter from $3.0 million in Q4 2021.
Nexalin Technology (NXL) Long-Term Deferred Tax (2021 - 2022) Analysis & Trends
Nexalin Technology's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $3.3 million for Q4 2022.
- In Q4 2022, Long-Term Deferred Tax rose 12.91% year-over-year to $3.3 million; the TTM figure through Dec 2022 stood at $3.3 million (up 12.91% YoY), while the FY2022 annual figure was $3.3 million, up 12.91% from the prior year.
- Long-Term Deferred Tax for Q4 2022 stood at $3.3 million, up from $3.0 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $3.3 million in Q4 2022, with the low at $3.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.95 Bn | 193.35 Bn | 7.27 Bn |
| 2 | Stryker | 128.10 Bn | 124.63 Bn | 4.50 Bn |
| 3 | Medtronic | 118.91 Bn | 109.69 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.43 Bn | 72.89 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn |
| 6 | Dexcom | 34.52 Bn | 32.58 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.94 Bn | 31.83 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn |
| 10 | Nexalin Technology | 6.98 Mn | 5.97 Mn | 8,897.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 3.34 Mn |
| Dec 31, 2021 | 2.96 Mn |